Keene, New Hampshire

  • Therapy Optimisation for the Treatment of Hairy Cell Leukemia

    Evaluation of remission status will take place 4 months after treatment. In addition, it will be tested whether patients with non-optimal response will have a benefit from a second cycle of cladribine. Non-optimal response is: patients with detectable residual disease; achievement of partial remission or detectable residual infiltration in the bone marrow.

    Phase

    2/3

    Span

    1235 weeks

    Sponsor

    University of Giessen

    Bad Neustadt

    Recruiting

  • Does Timing of VT Ablation Affect Prognosis in Patients With an Implantable Cardioverter-defibrillator?

    Enrolled patients will remain in a first phase of the study until the first appropriate ICD shock will be delivered. The objective of this first stage is to assess whether the burden of untreated non sustained VTs or episodes treated with anti-tachycardia pacing is predictive of appropriate ICD shocks. The second phase of the study will start after the first appropriate ICD shock delivered for VT. Patients will be then randomized to immediate VT ablation or to standard treatment, meaning waiting until next arrhythmic storm to perform a VT ablation procedure. The objective of this phase is compare the rate of worsening heart failure hospitalizations and deaths from any cause between the two groups.

    Phase

    N/A

    Span

    526 weeks

    Sponsor

    IRCCS San Raffaele

    Bad Neustadt

    Recruiting

  • Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

    MOMENTIS is a prospective, observational, single-arm, multicenter global study designed to collect real-world clinical outcomes in up to 500 subjects who have received the MITRIS RESILIA Mitral Valve, Model 11400M.

    Phase

    N/A

    Span

    677 weeks

    Sponsor

    Edwards Lifesciences

    Bad Neustadt

    Recruiting

1-3 of 3